Sana Biotechnology

SANA

Market cap $828M

Overview Fund Activity

3.22 USD

-0.18

5.29%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

3.22

0.00

0%

1 day

-5.29%

5 days

6.27%

1 month

3.54%

3 months

26.77%

6 months

10.27%

Year to date

95.15%

1 year

-28.92%

5 years

-90.83%

10 years

-90.83%

About: Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.

Employees: 194

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

83% more call options, than puts

Call options by funds: $1.74M | Put options by funds: $952K

58% more capital invested

Capital invested by funds: $252M [Q1] → $398M (+$147M) [Q2]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 47

1.77% less ownership

Funds ownership: 66.32% [Q1] → 64.54% (-1.77%) [Q2]

3% less funds holding

Funds holding: 160 [Q1] → 155 (-5) [Q2]

13% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 30

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$5

55% upside

Avg. target

$8.5

164% upside

High target

$12

273% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Morgan Stanley Maxwell Skor	$12	Overweight Assumed	3 Jul 2025
JMP Securities Reni Benjamin	$5	Market Outperform Reiterated	24 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about SANA published over the past 30 days

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (NASDAQ:SANA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Well, hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley.

Sana Biotechnology, Inc. (SANA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sana Biotechnology, Inc. (NASDAQ:SANA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

Sana Biotechnology, Inc. (NASDAQ:SANA ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President Thank you for being here. My name is Sam Semenkow, I'm one of the Biotech analysts here at Citi.

Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

Sana Biotechnology to Present at September 2025 Investor Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology to Present at September 2025 Investor Conferences

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common stock at a price to the public of $3.35 per share, pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Sana's previously announced underwritten public offering, which closed on August 8, 2025. All of the shares were sold by Sana. Total gross proceeds from the offering, including the full exercise of the underwriters' option, were approximately $86.3 million, before deducting underwriting discounts and commissions and other offering expenses.

Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Sana's allogeneic HIP technology achieved a first in T1D, showing insulin production and immune evasion without immunosuppression, but scalability remains unproven. Despite promising early data, Sana faces significant risks: cash burn, a small recent raise, key executive departures, and a long path to commercialization. Management's experience and the disruptive potential of HIP technology support my continued Buy rating, but I advise caution due to high risk and lack of near-term catalysts.

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

Sana Biotechnology Announces Pricing of Public Offering

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public offering of 20,895,522 shares of its common stock at a price to the public of $3.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,492,537 shares of common stock at a price to the public of $3.3499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,358,208 shares of its common stock. The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about August 8, 2025, subject to satisfaction of customary closing conditions.

Sana Biotechnology Announces Pricing of Public Offering

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass.

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

See News Rankings

Charts implemented using Lightweight Charts™